Skip to main content
    J

    Journey Medical Corp (DERM)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $3.70
    -0.63 (-14.55%)

    Market Cap: $122.24M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Journey Medical Corp (DERM) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Journey Medical (DERM) trades at 1.5x sales and 3.2x book value. Its P/S of 1.5x is above its 5-year median of 1.3x. Its forward P/E is 17.3x.

    Current Multiples

    Its enterprise value is 41.2x its EBITDA.

    MultipleValue
    P/E (trailing)N/A
    Forward P/E17.3x
    Price to sales1.5x
    Price to book3.2x
    EV/EBITDA41.2x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S1.5x1.3xN/A
    P/B3.2x5.2xN/A
    Medians of month-end values through Oct 2026: 56 to 60 months (5-year).

    Valuation History

    Over the 5 year ends shown, its P/S ranged from 0.5x in 2022 to 3.0x in 2025. 2025 was the highest of those years.

    Year endPriceP/SP/B
    2025$7.713.0x5.9x
    2024$3.911.4x4.3x
    2023$5.761.3x5.5x
    2022$1.920.5x2.0x
    2021$5.380.9x1.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About DERM

    What is DERM's forward P/E ratio?

    Journey Medical has a forward P/E ratio of 17.3x.

    Is DERM stock overvalued?

    GNG's valuation label for DERM is Undervalued.

    What is DERM's price to sales ratio?

    Journey Medical has a price to sales ratio of 1.5x.